GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » 50-Day SMA

Relmada Therapeutics (Relmada Therapeutics) 50-Day SMA : $4.66 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-05-11), Relmada Therapeutics's 50-Day SMA is $4.66. It's 20-Day SMA is $3.91 and 200-Day SMA is $3.77.


Competitive Comparison of Relmada Therapeutics's 50-Day SMA

For the Biotechnology subindustry, Relmada Therapeutics's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relmada Therapeutics's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's 50-Day SMA falls into.



Relmada Therapeutics  (NAS:RLMD) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relmada Therapeutics  (NAS:RLMD) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Relmada Therapeutics 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics (Relmada Therapeutics) Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Executives
Cedric O'gorman officer: Chief Medical Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa director, officer: Chief Executive Officer 138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly director 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel officer: EVP, Head of R&D 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence officer: Chief Financial Officer 3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo officer: Chief Medical Officer 71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar director P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth director 300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas officer: President and CSO 7707 GATEWAY BLVD, NEWARK CA 94560

Relmada Therapeutics (Relmada Therapeutics) Headlines

From GuruFocus